Dermatological Disorders

Illuvinate System Now Available for Plaque Psoriasis Treatment

By December 05, 2018

The treatment is based on the Goeckerman regimen which dates back to the 1920s and involves applying coal tar to a patient's skin and exposing the skin to ultraviolet light.

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Tx Option

By December 04, 2018

The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Mean Cumulative Lifetime Prevalence of Eczema 9.9%

December 04, 2018

The mean cumulative lifetime prevalence of atopic eczema is 9.9%, according to a research letter.

Upadacitinib Improves Pruritus in Moderate to Severe Atopic Dermatitis

November 19, 2018

Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.

Increased Risk of Depression, Suicide in Atopic Dermatitis

November 18, 2018

The prevalence of depression in patients with atopic dermatitis was higher than in those without atopic dermatitis.

Does Cetirizine Provide More Benefits Than Diphenhydramine for Acute Urticaria?

November 16, 2018

The change from baseline in 2-hour pruritus score was shown to be statistically noninferior from IV cetirizine to IV diphenhydramine, in favor of IV cetirizine.

FDA Fast-Tracks Treatment for Pachyonychia Congenita

By November 13, 2018

Through Palvella's proprietary QTORIN formulation, PTX-022 targets basal keratinocytes, which harbor the mutant keratin genes that cause PC.

New Topical Steroid Option for Plaque Psoriasis Soon to Be Available

By November 07, 2018

The approval was supported by data from 2 prospective, multicenter, randomized, double-blind clinical trials.

Dermatologic Adverse Events Common With Targeted Therapies, Immunotherapies

By November 06, 2018

"Closer collaboration between dermatologists and oncologists is essential," write the authors.

Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis

By November 06, 2018

Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.

Biosimilar Hyrimoz Gains FDA Approval

By November 01, 2018

The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality.

Altreno Now Available for Topical Treatment of Acne Vulgaris

By October 30, 2018

Altreno Lotion should be used with caution in patients with known sensitivity or allergy to fish.

Oral Acne Treatments

October 26, 2018

Oral medications for the treatment of acne including dosing for antibiotics, retinoids, and contraceptives.

Ilumya Now Available for the Treatment of Plaque Psoriasis

By October 23, 2018

Analyses presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2018 meeting, showed that compared with non-targeted treatments like apremilast, Ilumya was found to be the most cost-effective.

Caffeine Consumption and Rosacea Risk: What's the Link?

By October 17, 2018

Participants who responded to a question related to rosacea diagnosis in 2005 were included in the final analysis (N=82,737).

Phase 3 Trials Examine Efficacy of Tretinoin Lotion for Tx of Acne

October 16, 2018

The researchers found that tretinoin 0.05% lotion demonstrated statistically significant superiority to vehicle in reducing inflammatory and non-inflammatory lesion counts (both P<.001) at week 12, as well as improving acne severity (P<.001).

Bryhali Lotion Gets Tentative Approval for Plaque Psoriasis

By October 09, 2018

The approval of Bryhali was based on data from 2 randomized, double-blind studies conducted in 430 patients with moderate to severe plaque psoriasis.

Nuzyra Approved for CABP, Acute Skin/Skin Structure Infections

By October 03, 2018

The approval was based on Phase 3 data from 2 studies in ABSSSI, where treatment with Nuzyra was compared with linezolid, and 1 study in CABP comparing Nuzyra with moxifloxacin. Across all 3 trials, Nuzyra was found to be effective and generally safe and well-tolerated.

Seysara Approved for the Treatment of Moderate to Severe Acne Vulgaris

By October 02, 2018

The approval was based on data from 2 large, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving patients with moderate to severe facial acne vulgaris.

Qbrexza Now Available for the Treatment of Primary Axillary Hyperhidrosis

By October 01, 2018

A single cloth should be used to apply Qbrexza to both underarms.

First Treatment for Advanced Cutaneous Squamous Cell Carcinoma FDA-Approved

By October 01, 2018

The approval was based on data from 2 open-label studies where patients with metastatic CSCC or locally advanced CSCC who were not candidates for curative surgery or curative radiation received Libtayo 3mg/kg intravenously every 2 weeks for up to 48 weeks or up to 96 weeks until disease progression, unacceptable toxicity, or completion of planned treatment.

Patient Develops Rare Extrapulmonary Manifestation of Tuberculosis

By September 21, 2018

The patient, a 42-year-old female with systemic lupus erythematosus treated with mycophenolate mofetil and prednisone, reported swelling and pain in the fifth finger of her left hand for about 1-week.

RECELL System Approved to Treat Severe Burns

By September 21, 2018

At Week 8 post-treatment, 92% of the burn sites treated with RECELL System achieved complete healing vs 85% of sites treated with standard-of-care, demonstrating non-inferiority.

Contezolid Gets QIDP, Fast Track Status for Acute Bacterial Skin/Skin Structure Infections

By September 21, 2018

The structure of contezolid was designed to potentially reduce the risk of hematological toxicity associated with this class of antibiotics.

Dupilumab Beneficial in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

By September 18, 2018

The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.

Adalimumab Biosimilar Demonstrates Clinical Equivalence in Psoriasis Study

By September 13, 2018

The Phase 3 study (N=318) enrolled patients aged 18 to 78 years with moderate-to-severe chronic plaque psoriasis who had not previously received treatment with ≥1 biologic.

Novel Treatment for Pemphigus Granted Orphan Drug Designation

By September 13, 2018

Preliminary results from a Phase 1b proof-of-concept study showed that SYNT001 was associated with clinical improvement (as measured by Pemphigus Disease Area Index score) and induced a rapid reduction in lgG and circulating immune complex levels.

CAM Therapies and Psoriasis: Which Treatments Are Effective?

By September 11, 2018

To investigate the effectiveness of CAM modalities in the treatment of plaque psoriasis, researchers searched several databases to identify studies where CAM was used as an intervention.

Patient's Black Hairy Tongue Linked to Antibiotic Therapy

By September 10, 2018

The case involved a 55-year-old female patient who had been admitted to the hospital after suffering injuries from a car accident.

Oral JAK3 Inhibitor Granted Breakthrough Tx Designation for Alopecia Areata

By September 05, 2018

PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.